Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) generates news across respiratory support, blood monitoring, and emerging diagnostics, reflecting its role as a commercial-stage medical device company. Company announcements highlight the FDA-cleared INSPIRA ART100 cardiopulmonary support system, the development of the INSPIRA ART500 oxygenation platform, and progress with the HYLA non-invasive blood sensor, including completion of a clinical study and preparation for regulatory submission.
News coverage also follows Inspira’s strategic move into liquid biopsy diagnostics. The company has outlined a non-binding term sheet and proposed transaction to acquire an advanced liquid biopsy platform focused initially on breast cancer and circulating tumor cell analysis, alongside a concurrent equity investment and a contingent value rights framework for existing shareholders. These updates provide insight into how Inspira aims to extend its expertise in blood-based technologies into oncology diagnostics.
Investors and observers can expect IINN news to include regulatory milestones, such as submissions and anticipated approvals in markets like the United Arab Emirates, as well as updates on binding purchase orders, deployment timelines, and collaborations. Recent items have covered a registered direct offering, a Standby Equity Purchase Agreement, expansion of laboratory infrastructure, and an AI-based training alliance with Bites Learning Ltd. Leadership appointments and shareholder meeting notices also appear in the company’s news flow.
This news page aggregates these developments in one place, helping readers follow Inspira’s clinical, regulatory, commercial, and corporate updates over time.
Inspira (NASDAQ: IINN) said two previously announced binding purchase orders — $22.5 million (July 2, 2025) and $27 million (August 19, 2025) — have advanced to the final budgetary validation and fund allocation stage within relevant governmental procurement processes.
The company reported that ~91% of the orders have cleared commercial and administrative review and are undergoing the concluding budgetary authorization step prior to fund release and execution. Inspira expects payment and revenue recognition during the 2026 fiscal cycle, subject to customary governmental approvals, and says internal execution preparations are complete.
Inspira (NASDAQ: IINN) outlined a strategic vision and a proposed transaction framework to expand into liquid biopsy diagnostics through a contemplated acquisition of an advanced liquid biopsy platform and a concurrent equity investment. The company says the structure is designed to preserve shareholder value, enable future dividend distributions from its core respiratory and life-support technologies, and allocate value via a CVR framework. Inspira highlights its HYLA blood sensor (clinical accuracy reported at 95%–99% across measured parameters), an established blood diagnostics laboratory, and prior FDA 510(k) clearance of the ART100 system as foundations to accelerate regulatory and commercial progress for the new platform.
Inspira (NASDAQ: IINN) entered a non-binding term sheet dated Jan 5, 2026 for a proposed all‑share acquisition of an advanced liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment based on a $180 million pre-money valuation.
The company expects to sign Definitive Agreements within approximately four weeks, then seek shareholder approval and satisfy customary closing conditions. Inspira plans to allocate $12 million of the investment to existing respiratory and blood‑monitoring technology development. The acquired platform showed high concordance with tissue biopsies in clinical validation across dozens of samples and the company expects to pursue FDA 510(k) clearance; an existing reimbursement code is noted.
Inspira (NASDAQ: IINN) entered a non-binding term sheet on Jan 5, 2026 for an all-share acquisition of an advanced liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment based on a $180 million pre-money valuation. The Company expects to sign Definitive Agreements within ~four weeks, subject to shareholder approval and customary closing conditions.
The plan allocates $12 million of proceeds to existing respiratory and blood-monitoring technology development, proposes contingent value rights to protect current shareholders, and aims for FDA 510(k) clearance for the platform previously validated across dozens of patient samples.
Inspira Technologies (NASDAQ:IINN) reaffirmed its previously announced $49.5 million in binding purchase orders and said payment activity and revenue recognition are structured to commence in the 2026 fiscal cycle. The company said the orders remain in full force based on representations from its distributor and that execution timing reflects regulatory sequencing, technical implementation requirements, and coordination of institutional funding.
Inspira highlighted active coordination with distribution partners, regulators, and funding organizations to finalize delivery schedules, reduce execution risk, and support a phased rollout across target markets, and expects to provide further updates as milestones are met.
Inspira Technologies (NASDAQ: IINN, IINNW) entered a definitive agreement for a registered direct offering of 1,565,217 ordinary shares at $1.15 per share, producing gross proceeds of approximately $1.8 million. The offering is expected to close on or about December 16, 2025 and will be sold pursuant to a prospectus supplement under a Form F-3 shelf declared effective on December 12, 2025.
Separately, Inspira signed a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., giving the company the right to sell up to $25 million of ordinary shares over 36 months at its discretion, with no minimum purchase requirements. Net proceeds are intended for working capital and general corporate purposes.
Inspira Technologies (NASDAQ: IINN) said the Japan Patent Office granted Patent No. 7777598 on Dec 9, 2025 for its Convertible Dual Lumen Cannula and method of use, giving exclusive commercial rights in Japan through 2041.
The patent complements an earlier U.S. patent granted in 2023, creating IP protection across two major healthcare markets. The device converts a single-lumen cannula intravascularly into a dual-lumen cannula after insertion, aiming to let physicians switch modes without additional incisions. Management said this supports potential standalone disposable commercialization and integration into the INSPIRA™ ART System.
Inspira Technologies (NASDAQ: IINN) announced a strategic expansion of its core blood laboratory capabilities on December 3, 2025. The company plans to move into a substantially larger, state-of-the-art lab and expects the upgraded facility to be fully operational within the coming weeks. Key initiatives include increasing sample processing capacity, upgrading research instrumentation, and recruiting engineers and data-science experts to support blood-based clinical diagnostics and next-generation blood-analysis technologies.
The expansion is described as foundational to Inspira’s longer-term shift into broader diagnostic and blood-technology platforms and aims to accelerate development, integration of advanced diagnostics, and future growth. Further updates will be provided as operations ramp up and new technologies are integrated.
Inspira Technologies (NASDAQ: IINN) completed the clinical study for its HYLA non-invasive blood sensor on Nov. 13, 2025 and is progressing toward regulatory submission.
Company-reported results and ongoing lab tests show 95%–99% accuracy across measured parameters. Inspira said it will enter final validation and verification before submitting for approval and is integrating machine-learning to expand HYLA’s physiological parameter set beyond current non-invasive monitoring capabilities.
Inspira Technologies (NASDAQ: IINN) completed its regulatory submission of the FDA-cleared ART100 system to the United Arab Emirates Ministry of Health and Prevention (MOHAP) on Nov 6, 2025, and expects final approval within days.
The company said this milestone follows high-level UAE government discussions and positions ART100 for potential nationwide deployment and clinical integration across Gulf-region enterprise healthcare networks, advancing Inspira's global commercialization roadmap.
FAQ
What is the current stock price of Inspira Technologies Oxy Bhn (IINN)?
What is the market cap of Inspira Technologies Oxy Bhn (IINN)?
